Enzyme-activated fluorescent molecular precursor, and preparation method and application thereof

By designing enzyme-activated fluorescent molecular precursors and utilizing the exogenous enzyme CPG2 for specific activation at the tumor site, the problem of off-target activation of endogenous enzyme-activated probes was solved, achieving highly sensitive real-time tumor imaging.

CN121974830APending Publication Date: 2026-05-05SUZHOU INST OF BIOMEDICAL ENG & TECH CHINESE ACADEMY OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610016543.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-01-07
Publication Date
2026-05-05

AI Technical Summary

Technical Problem

Existing endogenous enzyme-activated fluorescent probes are prone to off-target activation in non-tumor tissues, leading to false positive signals, reducing diagnostic specificity, and making it difficult to achieve accurate intraoperative real-time pathological diagnosis.

Method used

A novel enzyme-activated fluorescent molecule precursor was developed. The exogenous enzyme CPG2 is specifically activated at the tumor site to release active fluorescent molecules. The fluorescent signal is enhanced by hydrolyzing the glutamate protecting group and spontaneously removing carbon dioxide through an enzymatic reaction.

Benefits of technology

It significantly improves the specificity and accuracy of tumor imaging, reduces background fluorescence signals, and achieves highly sensitive real-time tumor imaging.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121974830A_ABST
    Figure CN121974830A_ABST
Patent Text Reader

Abstract

The invention discloses an enzyme-activated fluorescent molecular precursor as well as a preparation method and application thereof. The enzyme-activated fluorescent molecular precursor has a chemical structure as shown in a formula I which is described in the specification. The invention develops an enzyme-activated fluorescent molecular precursor which can be used for real-time imaging of tumors by targeting exogenous enzyme to the tumors and specifically activating a probe at the tumors; according to the invention, the exogenous enzyme is introduced as an activation trigger, and normal cells do not have the exogenous enzyme, so that the problem of co-expression of the endogenous enzyme in non-tumor tissues can be avoided, background fluorescence signals can be reduced to the greatest extent, and the imaging specificity and accuracy are remarkably improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedical engineering, and in particular to an enzyme-activated fluorescent molecular precursor, its preparation method and application. Background Technology

[0002] Malignant tumors are a major threat to human health, and their treatment outcomes heavily depend on early, accurate diagnosis and complete resection. Real-time, high-specificity imaging is crucial for achieving precise intraoperative pathological diagnosis of malignant tumors. However, current clinical imaging techniques and histopathological methods are insufficient for real-time intraoperative tumor diagnosis. Furthermore, tissue biopsies rely on postoperative paraffin sections and immunohistochemistry, a time-consuming process that cannot meet the needs of in vivo point-of-care diagnosis. While traditional fluorescence imaging techniques have improved the signal-to-noise ratio to some extent, the presence of always-on fluorescent molecules in tumor imaging results in excessively high background fluorescence, severely limiting their clinical application.

[0003] To improve imaging specificity and diagnostic accuracy, activatable probes have emerged. These probes typically exhibit fluorescence quenching in their initial state, activating and emitting strong fluorescence only after specifically recognizing specific biomarkers within the tumor microenvironment, thereby significantly enhancing imaging contrast and the signal-to-noise ratio. Currently, most reported activatable fluorescent probes rely on chemical activation or endogenous enzyme activation mechanisms, such as activation by hydrogen peroxide, glutathione, endogenous enzymes like nitroreductase (NTR), aminopeptidase N (APN), and various matrix metalloproteinases (MMPs). These endogenous enzymes are often overexpressed in various malignant tumors, efficiently catalyzing the breaking of specific chemical bonds (such as amide bonds) in probe molecules, causing fluorophore release or conformational changes, thus achieving a fluorescence "on" response. While endogenous enzyme-activated probes demonstrate tumor specificity and show significant value in tumor imaging, their application remains limited by the issue of enzyme expression in non-tumor tissues.

[0004] Probes relying on endogenous enzyme activation cannot completely avoid off-target activation in normal tissues, potentially leading to false positives and reduced diagnostic specificity. Although endogenous enzyme-activated fluorescent probes have made significant progress in improving tumor / normal tissue (T / N) contrast, their inherent off-target risk still limits their clinical translation prospects. Developing next-generation probes with higher tumor specificity, faster activation kinetics, and lower non-specific background signal remains a key challenge for achieving accurate intraoperative real-time pathological diagnosis. Summary of the Invention

[0005] The technical problem this invention aims to solve is to address the shortcomings of the prior art by providing an enzyme-activated fluorescent molecular precursor, its preparation method, and its applications. This invention focuses on molecular probe design and applications in biomedical engineering, and also relates to enzymatic reactions in biochemistry. The core of this invention is the development of a novel fluorescent molecular precursor that can be activated and altered in fluorescence signal under the action of specific biological enzymes. It is primarily used for disease diagnosis and imaging at the cellular and in vivo levels, aiming to provide a highly sensitive fluorescence detection tool with low background interference.

[0006] To achieve the above objectives, the technical solution adopted by the present invention is as follows: In its first aspect, the present invention provides an enzyme-activated fluorescent molecular precursor, denoted as Compound I, which has the chemical structure shown in Formula I: .

[0007] This invention designs and synthesizes a fluorescent molecular precursor for targeted fluorescence activation in tumor tissues, such as, but not limited to, tumor fluorescence imaging. This fluorescent molecular precursor can be specifically activated at the tumor site by CPG2, releasing active fluorescent molecules and reducing background fluorescence.

[0008] Compound I can serve as a substrate for carboxypeptidase G2 (CPG2). Through enzymatic hydrolysis, it removes the glutamate protecting group and spontaneously releases carbon dioxide, releasing an active fluorescent molecule (compound II), which enhances the fluorescence signal. The process is shown below: A second aspect of the present invention provides a method for preparing the enzyme-activated fluorescent molecular precursor as described above, comprising the following steps: S1. Compound III was synthesized using compound II. The chemical structures of compound II and compound III are shown in formulas II and III, respectively. .

[0009] S2. The enzyme-activated fluorescent molecular precursor was synthesized using compound III.

[0010] Its synthetic route is as follows: Preferably, step S1 specifically includes: S1-1. Mix compound II, dichloromethane, DIPEA and 4-nitrophenyl chloroformate, and stir. S1-2: Disperse L-glutamic acid di-tert-butyl hydrochloride in dichloromethane, add the resulting mixture dropwise to the product obtained in step S1-1, and stir to react; S1-3. After the reaction is complete, the product is poured into brine and extracted with ethyl acetate. The organic phase is concentrated under vacuum. The concentrate is purified by silica gel column chromatography. The eluent is collected, concentrated and dried to obtain compound III.

[0011] Preferably, the eluent in steps S1-3 is a mixture of petroleum ether and ethyl acetate.

[0012] Preferably, step S1 specifically includes: S1-1: Mix 0.3-1.2 mmol of compound II, 2.5-10 mL of dichloromethane, 1-4 mmol of DIPEA and 0.4-1.5 mmol of 4-nitrophenyl chloroformate, and stir at room temperature for 0.5-2 h; S1-2: Disperse 0.5-2 mmol of L-glutamic acid di-tert-butyl hydrochloride in 2.5-10 mL of dichloromethane, and add the resulting mixture dropwise to the product obtained in step S1-1. Stir the mixture at room temperature for 0.5-2 h. S1-3. After the reaction is complete, the product is poured into 50-200 mL of saline solution and extracted with ethyl acetate. The extraction is repeated 1-4 times, each time using 50-2000 mL of ethyl acetate. The organic phases are combined and concentrated under vacuum. The concentrate is purified by silica gel column chromatography using a mixture of petroleum ether and ethyl acetate in a volume ratio of 1.5-6:1 as the eluent. The eluent is collected, concentrated, and dried to obtain compound III.

[0013] Preferably, step S2 specifically includes: Compound III was dissolved in a mixed solvent consisting of trifluoroacetic acid and deionized water, and the mixture was stirred to react. Then, deionized water was added to stop the reaction. The reaction product was separated and purified by high performance liquid chromatography to obtain the enzyme-activated fluorescent molecular precursor.

[0014] Preferably, step S2 specifically includes: 0.3-1.5 mmol of compound III was dissolved in 0.3-1.2 mL of a mixed solvent consisting of trifluoroacetic acid and deionized water in a volume ratio of 2-8:1. The mixture was stirred at room temperature for 2-3 h, and then deionized water was added to stop the reaction. The reaction product was separated and purified by high performance liquid chromatography to obtain the enzyme-activated fluorescent molecular precursor.

[0015] Preferably, the method for preparing the enzyme-activated fluorescent molecular precursor includes the following steps: S1. Synthesize compound III using compound II: S1-1, Mix 0.673 mmol of compound II, 5 mL of dichloromethane, 2.02 mmol of DIPEA and 0.808 mmol of 4-nitrophenyl chloroformate, and stir at room temperature for 1 h; S1-2, 1.0 mmol of L-glutamic acid di-tert-butyl hydrochloride was dispersed in 5 mL of dichloromethane, and the resulting mixture was added dropwise to the product obtained in step S1-1. The mixture was stirred at room temperature for 1 h. S1-3. After the reaction was completed, the product was poured into 100 mL of saline solution and extracted with ethyl acetate. The extraction was repeated twice, each time using 100 mL of ethyl acetate. The organic phases were combined and concentrated under vacuum. The concentrate was purified by silica gel column chromatography using a mixture of petroleum ether and ethyl acetate in a volume ratio of 3:1 as the eluent. The eluent was collected, concentrated, and dried to obtain compound III. S2. Dissolve 0.673 mmol of compound III in 0.673 mL of a mixed solvent consisting of trifluoroacetic acid and deionized water in a volume ratio of 4:1. Stir the mixture at room temperature for 3 h, then add deionized water to stop the reaction. The reaction product is separated and purified by high performance liquid chromatography to obtain the enzyme-activated fluorescent molecular precursor.

[0016] A third aspect of the present invention provides the use of the enzyme-activated fluorescent molecular precursor described above as a fluorescent activating agent for tumor tissue targeting or in the preparation of a fluorescent activating agent for tumor tissue targeting.

[0017] In a fourth aspect, the present invention provides the use of the enzyme-activated fluorescent molecular precursor described above as a tumor-specific fluorescent imaging agent or in the preparation of a tumor-specific fluorescent imaging agent.

[0018] The beneficial effects of this invention are: This invention develops an enzyme-activated fluorescent molecular precursor that can be used for real-time tumor imaging by targeting exogenous enzymes to tumors and specifically activating probes at the tumor site. By introducing exogenous enzymes as activation triggers, this invention avoids the problem of co-expression of endogenous enzymes in non-tumor tissues, since normal cells do not have such exogenous enzymes. This can minimize background fluorescence signals, thereby significantly improving imaging specificity and accuracy. Attached Figure Description

[0019] Figure 1 The image shows the 1H NMR (600 MHz, DMSO-d6) spectrum of compound II.

[0020] Figure 2 The image shows the 1H NMR (600 MHz, DMSO-d6) spectrum of compound I.

[0021] Figure 3 The image shows the 13C NMR (151 MHz, DMSO-d6) spectrum of compound I.

[0022] Figure 4 This is the high-resolution mass spectrum of compound I.

[0023] Figure 5 The reaction of compound I activated by CPG2 catalysis is characterized.

[0024] Figure 6 Cell imaging results for compounds II and I.

[0025] Figure 7 Cell imaging results of compound I at different concentrations of CPG2.

[0026] Figure 8 The image shows the imaging results of a nude mouse tumor model in the presence of compound I and CPG2. Detailed Implementation

[0027] The present invention will be further described in detail below with reference to embodiments, so that those skilled in the art can implement it based on the description.

[0028] It should be understood that terms such as “having,” “comprising,” and “including” as used herein do not exclude the presence or addition of one or more other elements or combinations thereof.

[0029] Unless otherwise specified, the experimental methods used in the following examples are conventional methods. Unless otherwise specified, the materials and reagents used in the following examples are commercially available. For examples where specific conditions are not specified, conventional conditions or conditions recommended by the manufacturer are followed. For reagents or instruments whose manufacturers are not specified, they are all commercially available products.

[0030] Compound II involved in this invention is an existing product, which can be obtained commercially or prepared in-house. In the following examples, reference is made to the literature "Aminopeptidase N Activatable Fluorescent Probe for Tracking Metastatic Cancer and Image-Guided Surgery via..." in Situ Spraying. J Am Chem Soc. The preparation was carried out according to 2020;142(13):6381–6389.” The NMR spectrum data of the prepared compound II are as follows: 1 H NMR (600 MHz, DMSO- d 6) δ 7.41 (d, J = 8.3 Hz, 2H), 7.18 (d, J = 15.9Hz, 1H), 7.04 (d, J= 15.9 Hz, 1H), 6.71 (s, 1H), 6.57 (d, J = 8.2 Hz, 2H), 5.83 (s, 2H), 2.57 (s, 2H), 2.51 (s, 2H), 1.00 (s, 6H).

[0031] Example 1 An enzyme-activated fluorescent molecular precursor is prepared by the following steps: S1. Synthesize compound III using compound II: S1-1. Compound II (194.8 mg, 0.673 mmol), 5 mL of dichloromethane, DIPEA (353 μL, 2.02 mmol) and 4-nitrophenyl chloroformate (162.9 mg, 0.808 mmol) were added to a 50 mL round-bottom flask and stirred at room temperature for 1 h. S1-2, Disperse L-glutamic acid di-tert-butyl hydrochloride (298.6 mg, 1.01 mmol) in 5 mL of dichloromethane, and add the resulting mixture dropwise to the product obtained in step S1-1. Stir the mixture at room temperature for 1 h. S1-3. After the reaction was completed, the product was poured into 100 mL of saline solution and extracted with ethyl acetate. The extraction was repeated twice, each time using 100 mL of ethyl acetate. The organic phases were combined and concentrated under vacuum. The concentrate was purified by silica gel column chromatography using a mixture of petroleum ether and ethyl acetate in a volume ratio of 3:1 as the eluent. The eluent was collected, concentrated, and dried to obtain compound III. S2. Compound III (approximately 386.79 mg, 0.673 mmol) was dissolved in 0.673 mL of a mixed solvent consisting of trifluoroacetic acid and deionized water in a volume ratio of 4:1. The mixture was stirred at room temperature for 2 h, and then deionized water was added to stop the reaction. The reaction product was separated and purified by high performance liquid chromatography to obtain compound I (58.9 mg, 0.127 mmol), which is the enzyme-activated fluorescent molecular precursor (orange solid), with a yield of 18.9%.

[0032] The spectral data of compound I are as follows: 1 H NMR (600 MHz, DMSO- d 6) δ 9.30 (s, 1H), 7.57 (d, J = 8.9 Hz, 2H), 7.44(d, J = 8.7 Hz, 2H), 7.23 (d, J = 2.7 Hz, 2H), 6.81 (s, 1H), 6.65 (d,J = 7.2 Hz, 1H), 4.01 (d, J = 6.7 Hz, 1H), 2.59 (s, 2H), 2.53 (s, 2H), 2.29 (d, J = 8.6 Hz, 1H), 2.21 (dd, J = 7.3, 2.3 Hz, 1H), 1.95–1.91 (m, 1H), 1.75 (dd, J = 8.1, 5.3Hz, 1H), 1.01 (s, 6H). 13 C NMR (151 MHz, DMSO- d 6) δ 174.5, 173.8, 170.3, 156.7, 154.3, 142.6, 138.2, 129.0, 128.5, 126.8, 121.6, 117.4, 114.2, 113.4, 74.9, 52.8, 42.4, 40.4, 38.2, 31.7, 28.9, 27.5. High-resolution mass spectrometry calculation of C. 25 H 27 O5N4 + The mass-to-charge ratio is 463.1976, and the actual measured value is 463.1965.

[0033] Performance testing 1. For the activation of compound I catalyzed by CPG2, the reaction conditions were as follows: 1 mL of reaction system contained 10 μM compound I, 50 mM tris(hydroxymethyl)aminomethane-HCl pH 7.3, 200 μM zinc chloride, and then carboxypeptidase G2 was added to a final concentration of 0.005 U / mL. The reaction was carried out at 37 degrees Celsius for 1 h. After dilution with 1 mL of PBS buffer, the fluorescence spectrum under 470 nm excitation light was detected by a fluorescence spectrometer.

[0034] The reference for expressing and purifying CPG2 protein is "Soluble expression, purification and functional characterisation of carboxypeptidase G2 and its individual domains". Protein Expr Purif. 2016;127:44–52.

[0035] 2. For the measurement of the interfering agent activated by compound I, add 10 μM compound I, 50 mM tris(hydroxymethyl)aminomethane-HCl pH 7.3, and 200 μM zinc chloride to a 4 mL reaction system, then add 1 mM of the interfering agent or a final concentration of 0.005 U / mL carboxypeptidase G2. React at 37 degrees Celsius for 1 h. Take 1 mL of the reaction solution, dilute it with 1 mL of PBS buffer, and detect the fluorescence spectrum under 470 nm excitation light using a fluorescence spectrometer.

[0036] Experimental results are as follows Figure 5 As shown, the optimal excitation wavelength for compound II standard sample in 50 mM tris(hydroxymethyl)aminomethane-HCl (pH 7.3) was 470 nm, and the optimal emission wavelength was 650 nm. At this excitation wavelength, the maximum emission wavelength of compound I was 605 nm. When carboxypeptidase G2 was added to the compound I solution, the fluorescence emission at 650 nm increased, while the emission at 605 nm decreased, and the detection limit for carboxypeptidase G2 was determined to be 0.000396 U / mL. Several selected substances were added (1. control; 2. 1 mM mg). 2+ 3.1 mM Ca 2+ 4.1 mM Zn 2+ 5. 1 mM DTT; 6. 1 mM cysteine; 7. 1 mM GSH; 8. 1 mM vitamin C; 9. 1 mM H2O2; 10. 0.005 U / mL carboxypeptidase G2 plus 200 μM zinc chloride) were reacted at 37°C for 40 min. The difference between the fluorescence emission values ​​at 650 nm and 605 nm under 470 nm excitation was measured and calculated. The results showed that only carboxypeptidase G2 could catalyze the activation of compound I, while it was stable for the other selected components.

[0037] 3. For cell imaging experiments, add 2×10⁻⁶ cells / mL to a 35 mm confocal dish. 5 4T1 cells were cultured overnight in 1 mL of culture medium to allow the cells to adhere. Then, compound II or compound I at a final concentration of 10 μM and carboxypeptidase G2 at 0-0.06 U / mL were added, and the mixture was reacted at 37 degrees Celsius for 40 min. The cells were then observed by fluorescence imaging using a confocal microscope.

[0038] Experimental results are as follows Figure 6 , Figure 7As shown, cell imaging under 488 nm excitation light was captured using a Nikon confocal microscope. Cells co-incubated with compound I showed significantly weaker red fluorescence compared to cells incubated with compound II. Subsequently, different concentrations of carboxypeptidase G2 (0-0.06 U / mL) were added to 4T1 cell culture dishes containing 10 μM compound I and incubated at 37°C for 40 min in a 5% CO2 incubator before confocal microscopy imaging. The addition of carboxypeptidase G2 enhanced cell fluorescence, starting with a relatively strong fluorescence at 0.01 U / mL, but further increases in enzyme concentration did not significantly enhance fluorescence.

[0039] 2.5 × 10 6 4T1 cells were transplanted into the right forearm periarthritis of naked Balb / c mice to establish an animal research model. The tumor-bearing mice were divided into two groups. Group 1 mice received a tail vein injection of compound I (2 mM, 150 μL) followed by intratumoral injection of CPG2 (final tumor site concentration 0.1 U / ml) or PBS. Group 2 mice received a tail vein injection of CPG2 (final systemic concentration 0.1 U / ml) or PBS followed by intratumoral injection of compound I (2 mM, 150 μL). Imaging was performed at different time points using a small animal imaging system (Aivis-L3, Guoke Zhiying).

[0040] Experimental results are as follows Figure 8 As shown, natural CPG2 lacks specific targeting ability. When injected into a tumor, it quickly enters the bloodstream through tumor vessels and is diluted and cleared by the blood. Therefore, the enzyme used to maintain an effective CPG2 concentration at the tumor site in the first group (left) was used to activate the probe. In the second group (right), significant fluorescence signals were observed at the tumor sites of mice at 30 and 60 min time points, indicating that compound I can be effectively cleaved and activated by CPG2 in the in vivo tumor environment to produce a sufficiently strong signal for imaging.

[0041] This invention combines cancer cell targeting technologies such as antibody targeting and CAR-T cell targeting (see Gardner, TJ et al., Nat. Chem. Biol. 2022, 18, 216) to achieve CPG2-catalyzed activation of fluorescent molecular precursors at tumor tissue. The fluorescent molecular precursor activation technology in this invention holds promise as a novel technique for tumor-specific fluorescence imaging.

[0042] Although the embodiments of the present invention have been disclosed above, they are not limited to the applications listed in the specification and embodiments. They can be applied to various fields suitable for the present invention. For those skilled in the art, other modifications can be easily made. Therefore, without departing from the general concept defined by the claims and their equivalents, the present invention is not limited to the specific details.

Claims

1. An enzyme-activated fluorescent molecular precursor, characterized in that, It has the chemical structure shown in Formula I: 。 2. A method for preparing the enzyme-activated fluorescent molecular precursor as described in claim 1, characterized in that, Includes the following steps: S1. Compound III was synthesized using compound II. The chemical structures of compound II and compound III are shown in formula II and formula III, respectively: ; S2. The enzyme-activated fluorescent molecular precursor was synthesized using compound III.

3. The method for preparing the enzyme-activated fluorescent molecular precursor according to claim 2, characterized in that, Step S1 is as follows: S1-1. Mix compound II, dichloromethane, DIPEA and 4-nitrophenyl chloroformate, and stir. S1-2: Disperse L-glutamic acid di-tert-butyl hydrochloride in dichloromethane, add the resulting mixture dropwise to the product obtained in step S1-1, and stir to react; S1-3. After the reaction is complete, the product is poured into brine and extracted with ethyl acetate. The organic phase is concentrated under vacuum. The concentrate is purified by silica gel column chromatography. The eluent is collected, concentrated and dried to obtain compound III.

4. The method for preparing the enzyme-activated fluorescent molecular precursor according to claim 3, characterized in that, The eluent in steps S1-3 is a mixture of petroleum ether and ethyl acetate.

5. The method for preparing the enzyme-activated fluorescent molecular precursor according to claim 4, characterized in that, Step S1 is as follows: S1-1: Mix 0.3-1.2 mmol of compound II, 2.5-10 mL of dichloromethane, 1-4 mmol of DIPEA and 0.4-1.5 mmol of 4-nitrophenyl chloroformate, and stir at room temperature for 0.5-2 h; S1-2: Disperse 0.5-2 mmol of L-glutamic acid di-tert-butyl hydrochloride in 2.5-10 mL of dichloromethane, and add the resulting mixture dropwise to the product obtained in step S1-1. Stir the mixture at room temperature for 0.5-2 h. S1-3. After the reaction is complete, the product is poured into 50-200 mL of saline solution and extracted with ethyl acetate. The extraction is repeated 1-4 times, each time using 50-2000 mL of ethyl acetate. The organic phases are combined and concentrated under vacuum. The concentrate is purified by silica gel column chromatography using a mixture of petroleum ether and ethyl acetate in a volume ratio of 1.5-6:1 as the eluent. The eluent is collected, concentrated, and dried to obtain compound III.

6. The method for preparing the enzyme-activated fluorescent molecular precursor according to claim 2, characterized in that, Step S2 is as follows: Compound III was dissolved in a mixed solvent consisting of trifluoroacetic acid and deionized water, and the mixture was stirred to react. Then, deionized water was added to stop the reaction. The reaction product was separated and purified by high performance liquid chromatography to obtain the enzyme-activated fluorescent molecular precursor.

7. The method for preparing the enzyme-activated fluorescent molecular precursor according to claim 2, characterized in that, Step S2 is as follows: 0.3-1.5 mmol of compound III was dissolved in 0.3-1.2 mL of a mixed solvent consisting of trifluoroacetic acid and deionized water in a volume ratio of 2-8:

1. The mixture was stirred at room temperature for 2-3 h, and then deionized water was added to stop the reaction. The reaction product was separated and purified by high performance liquid chromatography to obtain the enzyme-activated fluorescent molecular precursor.

8. The method for preparing the enzyme-activated fluorescent molecular precursor according to claim 2, characterized in that, Includes the following steps: S1. Synthesize compound III using compound II: S1-1, Mix 0.673 mmol of compound II, 5 mL of dichloromethane, 2.02 mmol of DIPEA and 0.808 mmol of 4-nitrophenyl chloroformate, and stir at room temperature for 1 h; S1-2, 1.0 mmol of L-glutamic acid di-tert-butyl hydrochloride was dispersed in 5 mL of dichloromethane, and the resulting mixture was added dropwise to the product obtained in step S1-1. The mixture was stirred at room temperature for 1 h. S1-3. After the reaction was completed, the product was poured into 100 mL of saline solution and extracted with ethyl acetate. The extraction was repeated twice, each time using 100 mL of ethyl acetate. The organic phases were combined and concentrated under vacuum. The concentrate was purified by silica gel column chromatography using a mixture of petroleum ether and ethyl acetate in a volume ratio of 3:1 as the eluent. The eluent was collected, concentrated, and dried to obtain compound III. S2. Dissolve 0.673 mmol of compound III in 0.673 mL of a mixed solvent consisting of trifluoroacetic acid and deionized water in a volume ratio of 4:

1. Stir the mixture at room temperature for 3 h, then add deionized water to stop the reaction. The reaction product is separated and purified by high performance liquid chromatography to obtain the enzyme-activated fluorescent molecular precursor.

9. The use of the enzyme-activated fluorescent molecular precursor as described in claim 1 as a fluorescent activating agent for tumor tissue targeting or in the preparation of a fluorescent activating agent for tumor tissue targeting.

10. The use of the enzyme-activated fluorescent molecular precursor as described in claim 1 as a tumor-specific fluorescent imaging agent or in the preparation of a tumor-specific fluorescent imaging agent.